Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 37, Issue -, Pages 1243-1247Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0371243
Keywords
angiogenesis; asymmetric dimethylarginine (ADMA); dimethylarginine dimethylaminohydrolase (DDAH); motility; nitric oxide; Rho GTPase
Categories
Funding
- British Heart Foundation [PG/07/004]
Ask authors/readers for more resources
ADMA (asymmetric dimethylarginine) is a cardiovascular risk factor and an endogenous inhibitor of NOS (nitric oxide synthase). ADMA is metabolized by DDAHs (dimethylarginine dimethylaminohydrolases). ADMA levels are increased in cardiovascular disorders associated with abnormal angiogenesis but the mechanisms are poorly understood. Recent studies show that altering ADMA metabolism in vivo and in vitro modulates the activity of Rho GTPases, key regulators of actin dynamics, endothelial cell motility and angiogenesis. in the present review, we consider this and other No-dependent and -independent molecular mechanisms by which the DDAH/ADMA pathway regulates angiogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available